Division of Gastroenterology and Hepatology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA.
Cold Spring Harbor Laboratory, Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.
Clin Gastroenterol Hepatol. 2021 Apr;19(4):845-847. doi: 10.1016/j.cgh.2020.02.045. Epub 2020 Feb 29.
Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognoses of all malignancies, with a 5-year survival rate <8%. Suspicious lesions are typically diagnosed via endoscopic ultrasound-guided fine-needle aspiration or endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB). Fewer needle passes decreases the risk of postprocedure complications, including pancreatitis and hemorrhage, while allowing additional needle passes to be used for adjuvant tissue testing, such as organoid creation and DNA sequencing.
胰腺导管腺癌 (PDAC) 的预后是所有恶性肿瘤中最差的之一,5 年生存率 <8%。疑似病变通常通过内镜超声引导下细针抽吸或内镜超声引导下细针活检 (EUS-FNB) 进行诊断。减少针数可以降低术后并发症的风险,包括胰腺炎和出血,同时可以为辅助组织检测(如类器官的创建和 DNA 测序)提供更多的针数。